Shilpa Medicare announces positive Phase 3 results for Oeris
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The partnership aligns with the launch of Oracle Health’s next-generation electronic health record
Enabling a new era in minimally invasive obesity treatment across Europe
The offering is expected to close on November 10, 2025, subject to customary closing conditions
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
Subscribe To Our Newsletter & Stay Updated